Alkem Laboratories announced the launch of single-shot pre-filled syringes containing semaglutide, a medication used for managing chronic conditions such as diabetes. The new pre-filled syringe format is designed to expand treatment options for patients by simplifying the administration process. Additionally, Alkem highlighted that this innovation aims to lower entry barriers by making the medication more affordable and accessible to a broader patient base in India. This development aligns with the company's commitment to improving healthcare delivery and patient convenience in the Indian pharmaceutical market. Alkem Laboratories said the one shot pre-filled syringe format expands treatment options for patients and lowers entry barriers by making it affordable.